Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BASF Readies Medical Food Product

By Meagan Parrish | November 14, 2017

BASF has entered a partnership to develop a “first-of-its-kind” medical food product.

Under the  agreement, BASF will lend scientific expertise and manufacturing capabilities, while DIEM Labs will market and sell the product. The medical food will be designed to help patients with Non-Alcoholic Fatty Liver Disease (NAFLD).

BASF hasn’t disclosed what exactly will be in the medical food, but the product is reportedly being developed in the same division that works on the company’s Omega 3 chemistry.

NAFLD rates are rising in America and are linked to obesity and metabolic syndrome. At the moment there is no food product on the market to help with NAFLD patients’ dietary needs.

“With this step, BASF is entering an attractive new market segment in the space between human nutrition and pharma,” François Scheffler, head of BASF’s Global Human Nutrition and Pharma Solutions Businesses, said.

BASF has already conducted its own trial with 170 patients to test the product’s efficacy and plans to launch the product in the U.S. Unlike pharmaceuticals, medical foods are not required to undergo a premarket review by the U.S. Food and Drug Administration.

Several other companies have been developing products for the medical foods space, Codexis and Nestle.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE